Duration of emicizumab course and duration of all AHA treatment by rituximab status (N = 62). Duration of emicizumab course was calculated for entire cohort (N = 62). Duration of all AHA treatment was defined as the amount of time patients were on emicizumab and/or immunosuppression therapy (if applicable) for the indication of AHA. The median time for the 37 patients in the cohort who had completed emicizumab and IST (if applicable) at the time of data collection cutoff was 18 weeks. Patients were censored at death or if follow-up time ended before discontinuing therapy (indicated with an X on graph).